Multi-provincial Cohort for Hypertension (MUCH)

• Conditions: Hypertension
• Interventions: Drug: Antihypertensive Agents; Other: Cardiovascular risk factors

• Registration Number: NCT03150888
• Lead Sponsor: Beijing Institute of Heart, Lung and Blood Vessel Diseases

Brief Summary

The purpose of this study is to construct hypertension specialized cohort using uniform standards and specifications. This study timely collected multi-dimensional clinical information through electronic medical records, mobile health, data integration, informatics and computer modern techniques, linking self-reported data and big data platforms from different sources to timely obtain the incidence and mortality data, and integrating hypertension cohort samples and the associated clinical records systematically, in order to build a 30-thousand hypertension specialized cohort with fine phenotypic data and blood/urine samples, thus far to provide support for the development of precise medicine research and related industries.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-05-04
• Study First Submitted QC: 2017-05-10
• Study First Posted: 2017-05-12
• Study Start: 2017-07-03
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-21
• Last Update Posted: 2020-01-22
• Primary Completion: 2020-12
• Study Completion: 2020-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30000

Inclusion Criteria

• Clinical diagnosis of hypertension
• over 18 years old
• ti sign the informed consent

Exclusion Criteria

• with life-threatening severe disease, such as severe tumor or AIDs
• pregnancy or lactating women,or plan to pregnant within half a year,
• with severe mental disorders
• participating in clinical trials

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Community based hypertension cohort	Cardiovascular risk factors	-
Community based hypertension cohort	Antihypertensive Agents	-
Hospital based hypertension cohort	Antihypertensive Agents	-
Hospital based hypertension cohort	Cardiovascular risk factors	-

Primary Outcome Measures

Name	Time	Method
Composite end point of major cardiovascular and cerebrovascular events	From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year	Composite end point of major cardiovascular and cerebrovascular events

Secondary Outcome Measures

Name	Time	Method
New-onset of cardiovascular events	From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year	New-onset of cardiovascular events
Total death	From date of enrollment until date of death from all cause, assessed up to 3 year	Total death
New-onset of stroke	From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year	New-onset of stroke
Major bleeding	From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year	Major bleeding
Atrial fibrillation	From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year	Atrial fibrillation

Trial Locations

Locations (6)

Beijing Tsinghua Chang Gung Hospital; 🇨🇳 Beijing, China

Southwest Hospital, China; 🇨🇳 Chongqing, China

Nanfang Hospital of Southern Medical University; 🇨🇳 Guangzhou, China

Beijing Tiantan Hospital; 🇨🇳 Beijing, China

Ruijin Hospital; 🇨🇳 Shanghai, China

Beijing Anzhen Hospital; 🇨🇳 Beijing, China